ACET Insider Trading
Adicet Bio, Inc. | Pharmaceutical Preparations
Comprehensive Trading Performance Summary
The investment history of corporate insiders at Adicet Bio, Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2025-10-11 03:06 | 2025-10-08 | ORBIMED ADVISORS LLC | 10% owner | BUY | $1.00 | 5,000,000 | $5,000,000 | 4,490,254 | +100.0% |
| 2024-06-07 23:05 | 2024-06-05 | Kauffman Michael | Director | SELL | $1.43 | 5,900 | $8,437 | 5,900 | -50.0% |
| 2024-01-27 03:14 | 2024-01-25 | ORBIMED ADVISORS LLC | Director, 10% owner | BUY | $2.40 | 3,125,000 | $7,500,000 | 1,255,985 | +100.0% |
| 2024-01-27 03:13 | 2024-01-25 | GORDON CARL L | Director, 10% owner | BUY | $2.40 | 3,125,000 | $7,500,000 | 1,255,985 | +100.0% |
| 2023-10-03 03:16 | 2023-09-28 | Schor Chen | Director, Officer - President & CEO | SELL | $1.39 | 11,000 | $15,290 | 176,969 | -5.9% |
| 2023-10-03 03:16 | 2023-09-28 | Schor Chen | Director, Officer - President & CEO | BUY | $1.38 | 11,000 | $15,149 | 43,469 | +33.9% |
| 2023-06-30 23:08 | 2023-06-30 | DUBIN STEVE | Director | BUY | $2.40 | 5,000 | $12,000 | 10,900 | +84.7% |
| 2023-06-29 23:51 | 2023-06-27 | GORDON CARL L | Director, 10% owner | BUY | $2.09 | 875,000 | $1,828,750 | 748,054 | +100.0% |
| 2023-06-29 23:46 | 2023-06-27 | ORBIMED ADVISORS LLC | Director, 10% owner | BUY | $2.09 | 875,000 | $1,828,750 | 748,054 | +100.0% |
| 2023-02-18 04:22 | 2023-02-15 | Healey Don | Officer - Chief Technology Officer | SELL | $7.57 | 4,533 | $34,327 | 66,568 | -6.4% |
| 2023-02-15 00:50 | 2023-02-10 | Healey Don | Officer - Chief Technology Officer | SELL | $7.98 | 10,467 | $83,476 | 71,101 | -12.8% |
| 2022-11-16 00:32 | 2022-11-10 | Aftab Blake | Officer - Chief Scientific Officer | SELL | $21.00 | 6,967 | $146,307 | 28,209 | -19.8% |
| 2022-11-16 00:31 | 2022-11-10 | Schor Chen | Director, Officer - President & CEO | SELL | $20.30 | 39,955 | $811,242 | 53,424 | -42.8% |
| 2022-11-10 00:05 | 2022-11-07 | Schor Chen | Director, Officer - President & CEO | SELL | $19.05 | 30,000 | $571,488 | 83,424 | -26.4% |
| 2022-11-05 00:23 | 2022-11-02 | Schor Chen | Director, Officer - President & CEO | SELL | $18.04 | 25,313 | $456,717 | 113,424 | -18.2% |
| 2022-10-21 23:10 | 2022-10-19 | Aftab Blake | Officer - Chief Scientific Officer | SELL | $16.27 | 8,067 | $131,250 | 35,176 | -18.7% |
| 2022-10-14 23:08 | 2022-10-12 | Aftab Blake | Officer - Chief Scientific Officer | OPT+S | $15.40 | 1,646 | $25,348 | 51,176 | 0.0% |
| 2022-09-17 00:51 | 2022-09-14 | Schor Chen | Director, Officer - President & CEO | SELL | $18.00 | 952 | $17,136 | 138,737 | -0.7% |
| 2022-09-13 23:59 | 2022-09-09 | Schor Chen | Director, Officer - President & CEO | SELL | $16.80 | 78,412 | $1,317,220 | 139,689 | -36.0% |
| 2022-08-06 01:43 | 2022-08-03 | Aftab Blake | Officer - Chief Scientific Officer | SELL | $18.00 | 6,968 | $125,424 | 38,967 | -15.2% |
| 2022-08-03 23:16 | 2022-08-01 | Aftab Blake | Officer - Chief Scientific Officer | SELL | $16.64 | 6,968 | $115,948 | 45,935 | -13.2% |
| 2022-07-08 00:12 | 2022-07-05 | Aftab Blake | Officer - Chief Scientific Officer | SELL | $14.50 | 1,363 | $19,764 | 52,903 | -2.5% |
| 2022-04-06 01:23 | 2022-04-01 | Galimi Francesco | Officer - SVP & Chief Medical Officer | OPT+S | $21.00 | 15,600 | $327,600 | 59,917 | 0.0% |
| 2022-03-12 00:08 | 2022-03-09 | Jakobovits Aya | Director | SELL | $14.00 | 4,000 | $56,000 | 356,345 | -1.1% |
| 2022-02-18 02:10 | 2022-02-16 | Jakobovits Aya | Director | SELL | $14.83 | 4,000 | $59,328 | 358,345 | -1.1% |
| 2022-02-15 01:28 | 2022-01-03 | Jakobovits Aya | Director | SELL | $16.51 | 24,000 | $396,158 | 360,345 | -6.2% |
| 2021-12-14 02:00 | 2021-12-08 | Sinclair Andrew | Director | BUY | $14.00 | 500,000 | $7,000,000 | 2,115,385 | +31.0% |
| 2021-12-11 01:30 | 2021-12-08 | Sinclair Andrew | Director | BUY | $14.00 | 500,000 | $7,000,000 | 2,140,721 | +30.5% |
| 2021-06-21 23:25 | 2021-06-16 | Schor Chen | Director, Officer - President & CEO | SELL | $10.53 | 16,466 | $173,443 | 89,836 | -15.5% |
| 2021-06-18 01:08 | 2021-06-15 | Jakobovits Aya | Director | SELL | $11.16 | 3,847 | $42,919 | 215,883 | -1.8% |
| 2021-06-08 02:12 | 2021-06-03 | Schor Chen | Director, Officer - President & CEO | SELL | $12.06 | 16,466 | $198,499 | 98,818 | -14.3% |
| 2021-05-21 23:34 | 2021-05-19 | Schor Chen | Director, Officer - President & CEO | SELL | $13.45 | 16,466 | $221,436 | 107,800 | -13.3% |
| 2021-05-21 02:28 | 2021-05-18 | Jakobovits Aya | Director | SELL | $14.09 | 8,000 | $112,746 | 217,806 | -3.5% |
| 2021-05-14 23:33 | 2021-05-12 | Jakobovits Aya | Director | SELL | $13.23 | 10,000 | $132,332 | 221,806 | -4.3% |
| 2021-05-07 23:02 | 2021-05-05 | Schor Chen | Director, Officer - President & CEO | SELL | $14.22 | 16,466 | $234,222 | 116,782 | -12.4% |
| 2021-04-22 23:34 | 2021-04-20 | Schor Chen | Director, Officer - President and CEO | SELL | $12.01 | 16,466 | $197,676 | 104,777 | -13.6% |
| 2021-04-08 23:37 | 2021-04-06 | Schor Chen | Director, Officer - President and CEO | SELL | $13.04 | 16,466 | $214,700 | 112,261 | -12.8% |
| 2021-04-02 01:48 | 2021-03-30 | Schor Chen | Director, Officer - President and CEO | SELL | $12.85 | 16,466 | $211,639 | 119,745 | -12.1% |
| 2021-03-19 04:55 | 2021-03-16 | Schor Chen | Director, Officer - President and CEO | SELL | $15.34 | 16,466 | $252,559 | 127,229 | -11.5% |
| 2019-02-27 16:26 | 2019-02-26 | DEBENEDITTIS FRANK | Officer - Sr. Vice President | SELL | $0.21 | 47,130 | $10,114 | 44,467 | -51.5% |
| 2018-12-27 00:45 | 2018-12-26 | Scally Frances P | Officer - SVP, CHIEF ACCOUNTING OFFICER | SELL | $0.91 | 183 | $167 | 16,917 | -1.1% |
| 2018-10-05 20:43 | 2018-10-04 | Rogers Steven | Officer - SVP, CHIEF LEGAL OFFICER | SELL | $2.31 | 645 | $1,492 | 34,500 | -1.8% |
| 2018-10-05 20:41 | 2018-10-04 | EILENDER ALBERT L | Director, Officer - Chairman | SELL | $2.30 | 2,000 | $4,600 | 297,313 | -0.7% |
| 2018-10-05 20:40 | 2018-10-05 | DEBENEDITTIS FRANK | Officer - Sr. Vice President | SELL | $2.28 | 895 | $2,041 | 91,597 | -1.0% |
| 2018-10-05 20:39 | 2018-10-04 | Alaimo Charles John | Officer - SENIOR VICE PRESIDENT | SELL | $2.37 | 731 | $1,732 | 21,587 | -3.3% |
| 2018-09-07 23:09 | 2018-09-07 | Rogers Steven | Officer - SVP, CHIEF LEGAL OFFICER | SELL | $3.33 | 3,769 | $12,563 | 33,531 | -10.1% |
| 2018-09-07 23:09 | 2018-09-07 | Kaczmarek Walter J III | Officer - Chief Operating Officer | SELL | $3.33 | 6,400 | $21,302 | 56,782 | -10.1% |
| 2018-09-07 23:08 | 2018-09-07 | EILENDER ALBERT L | Director, Officer - Chairman | SELL | $3.29 | 10,700 | $35,220 | 294,672 | -3.5% |
| 2018-09-07 23:07 | 2018-09-07 | DEBENEDITTIS FRANK | Officer - Sr. Vice President | SELL | $3.33 | 2,800 | $9,312 | 90,575 | -3.0% |
| 2018-09-07 18:53 | 2018-09-05 | Scally Frances P | Officer - SVP, CHIEF ACCOUNTING OFFICER | SELL | $3.29 | 789 | $2,596 | 17,100 | -4.4% |
How to Interpret $ACET Trades
Not every insider transaction in Adicet Bio, Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $ACET shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for ACET
Insider activity data for Adicet Bio, Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $ACET, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.